In-Vitro Toxicology Testing Market Report 2026

The in-vitro toxicology testing market size has grown rapidly in recent years. It will grow from $12.73 billion in 2025 to $14.11 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to ethical concerns over animal testing, increasing pharmaceutical r and d activity, early adoption of cell-based assays, regulatory restrictions on animal testing, growth in cosmetic safety testing.

The in-vitro toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $20.87 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to advancements in toxicogenomics and predictive modeling, rising demand for personalized medicine safety testing, increasing investment in alternative testing technologies, expanding regulatory frameworks supporting in vitro methods, growth of biotechnology and biopharmaceutical pipelines. Major trends in the forecast period include increasing shift from in vivo to in vitro toxicology models, rising adoption of high-throughput screening technologies, growing demand for early-stage toxicity assessment in drug discovery, expansion of cell-based and organ-on-chip assays, increasing regulatory acceptance of alternative toxicology methods.

Rising healthcare expenditure is expected to drive the growth of the in-vitro toxicology testing market in the coming years. Healthcare expenditure refers to the amount of money spent by individuals and governments from total income on hospitals, home healthcare services, prescription drugs, nursing facilities, and personal healthcare. Globally, healthcare spending is increasing due to the rising prevalence of diseases that require in-vitro toxicology testing. For example, in September 2024, a report published by the Centers for Medicare & Medicaid Services, a US federal agency, indicated that from 2023 to 2032, the average annual growth rate of national health expenditure (NHE) is projected to be 5.6%, exceeding the average GDP growth rate of 4.3%. Consequently, the share of healthcare spending as a percentage of GDP is expected to increase from 17.3% in 2022 to 19.7% in 2032. Therefore, the rising healthcare expenditure is fueling the growth of the in-vitro toxicology testing market.

Major companies in the in-vitro toxicology testing market are increasingly adopting strategic partnerships to offer inhalation toxicology tests and strengthen their market position. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve mutual benefits and success. For example, in November 2024, Charles River Laboratories International Inc., a US-based provider of pharmaceutical products and services, partnered with MatTek Life Sciences, a US-based biotechnology company, to develop a new approach methodology (NAM) inhalation toxicology test aimed at reducing dependence on traditional animal research methods. By incorporating MatTek’s advanced 3D human tissue models into toxicology testing workflows, this collaboration can help bridge the gap between animal testing and human biology.

In September 2024, Scantox Group, a Denmark-based preclinical contract research organization specializing in toxicology, pharmacology, and regulatory safety studies, acquired Gentronix Ltd for an undisclosed amount. Through this acquisition, Scantox Group gains access to Gentronix’s specialized in-vitro and genetic toxicology assay portfolio, GLP-compliant laboratory capabilities, and established client network, thereby enhancing its regulatory toxicology capabilities while expanding operational scale and service breadth across early-stage safety assessment. Gentronix Ltd., a UK-based biotechnology company, specializes in genetic toxicology testing solutions and is recognized for its expertise in in-vitro genotoxicity assays, skin toxicology studies, and predictive toxicology innovations.

Major companies operating in the in-vitro toxicology testing market are Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings (LabCorp), Gentronix Limited (a subsidiary of Eurofins Scientific SE), Bio-Rad Laboratories Inc., Eurofins Scientific SE, Charles River Laboratories International Inc., Promega Corporation, Agilent Technologies Inc., Evotec SE, SGS SA, BioIVT LLC, MB Research Laboratories LLC, Creative Biolabs Inc., Creative Bioarray Inc., InSphero AG, PerkinElmer Inc., Cyprotex PLC, MatTek Corporation, Danaher Corporation, Ncardia AG, Sekisui Chemical Co. Ltd., BioReliance Corporation, CellSystems Biotechnologie Vertrieb GmbH, Taconic Biosciences Inc., Biopredic International, MultiCell Technologies Inc., Altasciences Clinical Research Holdings Inc., Molecular Toxicology Inc., Toxys BV, XenoTech LLC, Optivia Biotechnology Inc., Toxikon Corporation.

North America was the largest region in the in- vitro toxicology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the in- vitro toxicology testing market report during the forecast period. The regions covered in the in-vitro toxicology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vitro toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the in-vitro toxicology testing market by increasing costs for imported reagents, laboratory consumables, analytical equipment, and high-throughput screening systems. Pharmaceutical and cosmetic industries in regions such as north america and europe are most affected due to reliance on global supply chains. These tariffs may elevate testing costs and extend development timelines. However, they are also encouraging local manufacturing, supply chain diversification, and innovation in cost-efficient toxicology platforms.

The in-vitro toxicology testing market research report is one of a series of new reports that provides in-vitro toxicology testing market statistics, including in-vitro toxicology testing industry global market size, regional shares, competitors with a in-vitro toxicology testing market share, detailed in-vitro toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro toxicology testing industry. This in-vitro toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In-vitro toxicology testing refers to assays and tests used to determine toxic doses of drugs, nutraceuticals, and food additives that cause toxicity when administered. It is used to detect the presence of toxic chemicals, and residual solvents and reduce hazardous exposure. This testing is mostly used to determine the doses of medications that exhibit toxicity in preclinical development, along with drug discovery and development.

The main products of in-vitro toxicology testing are consumables, assays, equipment, software, and services. Consumables refer to all the products that are used in laboratory testing of compounds such as cannulas and lancets. The methods involved cellular assays, biochemical assays, in silico models, and ex vivo models, and technologies involved are cell culture technologies, high-throughput technologies, and toxicogenomic, applied under various application involving neurotoxicity, dermal toxicity, cytotoxicity, and other applications. The various industry verticals included pharmaceuticals and biopharmaceuticals, cosmetic and household products, food, and chemicals.

The in-vitro toxicology testing market includes revenues earned by entities by providing metabolic, toxicokinetic, and bioanalytical investigations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.